About the company
Delcath Systems is a small medical technology company from New York. It markets a system called Hepzato that delivers a high dose of a cancer drug directly to the liver, for treating liver metastases from eye melanoma. As of Oct 12, 2026
Where is the price relative to the buy zone?
Analysis from Watcher
Delcath Systems belongs to the extended universe: 361 more US stocks that we analyze once a week (on Saturdays) – with buy zone, analysis charts and your own alerts. This universe is part of the Watcher plan (€9.99 per month).
Free remain the screener with all symbols of the core universe, their analysis charts, the fundamental analysis, the market analysis and the Academy.
See plans and pricing To the screener
Already have an account with Watcher? Log in
More stocks from Other stocks
Automated chart analysis, not investment advice – the decision and the risk are yours. Risk notice and investment advice